A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study.
Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
Study Status: Active, not recruiting
Non-Small Cell Lung Cancer
Drug: erlotinib HCl
Information provided by:
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
Paula O`Connor, M.D.., Study Director